Zenith
Epigenetics

Zenith Epigenetics Ltd. is a clinical stage biotechnology company developing best in class bromodomain (BET) inhibitors for the treatment of cancer and other disorders with significant unmet medical need. Our goal is to be a leading epigenetic company translating bromodomain biology into impactful therapies.

Learn More

About Zenith Epigenetics

Zenith Epigenetics Ltd. ("Zenith Epigenetics") is a clinical stage biotechnology company developing best in class bromodomain and extraterminal domain protein (BET) inhibitors for the treatment of cancer and other disorders with significant unmet medical need. Our cutting edge epigenetic platform of innovative biology and chemistry has generated differentiated, potent and selective BET inhibitors. Our goal is to be a leading epigenetic company translating bromodomain biology into impactful therapies.

Our lead BET inhibitor (BETi), ZEN-3694, is in Phase 2 clinical development for treatment of metastatic castration resistant prostate cancer (mCRPC) and will be entering a Phase 1b/2 clinical trial in collaboration with Pfizer for triple negative breast cancer (TNBC) in early 2019.

Our strong management team and organization allow us to efficiently develop BETi combination therapies for multiple indications. Our research team, based in Calgary, Alberta, with its broad and longstanding experience in epigenetics, is a leader in the discovery of pan and selective BET inhibitors in oncology and other indications. The development activities are led by our San Francisco based team where a strong emphasis on translational medicine, to drive patient pre-selection, combined with a proven track record in drug development allows us to excel in the field of epigenetics.

Zenith Epigenetics is a wholly-owned subsidiary of Zenith Capital Corp.

SIGN-UP FOR NEWS ALERTS HERE

Events
May
31

American Society of Clinical Oncology Annual Meeting 2019

Zenith will be attending and participating at the 2019 American Society of Clinical Oncology Annual Meeting (ASCO.2019) from May 31 - June 4, 2019.

Read More Add This to my Calendar
Mar
29

American Association for Cancer Research 2019

Zenith will be participationg at the 2019 American Association for Cancer Research (AACR 2019) from March 29 - April 3.

Read More Add This to my Calendar
Mar
27

Bio Europe Spring 2019

Zenith will be attending Bio Europe Spring 2019 in Vienna, Austria from March 25-27. Zenith will be presenting at 11:00 am (local time) on Wednesday, March 27, 2019 in room Schubert 5 on level 1.

Read More Add This to my Calendar